Indoleamine 2,3-dioxygenase cells correspond to the BDCA2 plasmacytoid dendritic cells in human melanoma sentinel nodes

Journal of Investigative Dermatology

Volumn 130, Issue 3, 2010, Pages 898-901

  Gerlini, Gianni ^a   Di Gennaro, Paola ^b   Mariotti, Giulia ^b   Urso, Carmelo ^a   Chiarugi, Alberto ^b   Pimpinelli, Nicola ^b   Borgognoni, Lorenzo ^a  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE;

CANCER IMMUNOLOGY; CELL PROLIFERATION; DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; LETTER; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENTINEL LYMPH NODE; TUMOR IMMUNITY;

DENDRITIC CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LECTINS, C-TYPE; LYMPH NODES; MELANOMA; MEMBRANE GLYCOPROTEINS; RECEPTORS, IMMUNOLOGIC; SKIN NEOPLASMS;

EID: 76649114336     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.307     Document Type: Letter

References (21)

1. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K et al. (2008) Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 181:776-784
2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. (2000) Immunobiol-ogy of dendritic cells. Annu Rev Immunol 18:767-811
3. Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, Fuchs D et al. (2007) HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109:3351-3359
4. Cochran AJ, Huang R, Lee J, Itakura E, Leong SPL, Essner R (2006) Tumor-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659-670
5. Dzionek A, Sohma Y, Nagafune J, Cella M, Colonna M, Facchetti F et al. (2001) BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med 194:1823-1834
6. Gerlini G, Urso C, Mariotti G, Di Gennaro P, Palli D, Brandani P et al. (2007) Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol 125:184-193
7. Gilliet M, Liu YJ (2002) Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol 63:1149-1155 (Pubitemid 36025989)
8. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M et al. (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-trypto-phan correlates with antitumor responses. Cancer Res 67:792-801
9. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA et al. (2007) Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 204:105-115
10. Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE et al. (2003) Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 83:1457-1466
11. Liu H, Liu L, Fletcher BS, Visner GA (2006) Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J 20:2384-2386
12. Liu YJ (2001) Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 106:259-262
13. Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG et al. (2008) Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 14:4532-4542
14. Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A et al. (2007) Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13:2961-2969
15. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunor-egulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312-319
16. Munn DH, Mellor AL (2007) Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147-1154
17. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ et al. (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114: 280-290
18. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB et al. (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297:1867-1870
19. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B et al. (1998) Prevention of allogeneic fetal rejection by trypto-phan catabolism. Science 281:1191-1193
20. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Antonenko S et al. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835-1837
21. Vuylsteke RJ, van Leeuwen PA, Meijer S, Wijnands PG, Statius Muller MG, Busch DH (2002) Sampling tumor-draining lymph nodes for phenotypic and functional analysis of dendritic cells and T cells. Am J Pathol 16:19-26